

On-line Table: Baseline patient characteristics^a

| | Kyphoplasty (n = 191) ^b | Vertebroplasty (n = 190) ^b |
|---|---------------------------------------|--|
| Denominator (No.) | 191 | 190 |
| Age (yr) (mean) (SD) | 75.5 (10.3) | 75.7 (10.5) |
| Weight (kg) (mean) (SD) | 69.9 (18.2) | 72.7 (19.5) |
| Height (cm) (mean) (SD) | 162 (11.0) | 164 (10.2) |
| Body mass index (mean) (SD) | 26.5 (5.8) | 27.0 (6.3) |
| Female (m) (%) | 151 (79.1) | 144 (75.8) |
| Etiology (m) (%) | | |
| Primary osteoporosis | 179 (93.7) | 172 (90.5) |
| Secondary osteoporosis | 12 (6.3) | 18 (9.5) |
| Index fractures (m) (%) | | |
| 1 | 149 (78.0) | 150 (78.9) |
| 2 | 33 (17.3) | 32 (16.8) |
| 3 | 9 (4.7) | 8 (4.2) |
| Estimated index fracture age (days) (median) (IQR) | 24.5 (13.0–46.0) | 25.0 (14.0–56.0) |
| Prevalent fractures used for stratification (m) (%) | | |
| 1 | 111 (58.1) | 107 (56.3) |
| 2 | 44 (23.0) | 47 (24.7) |
| ≥3 | 36 (18.8) | 36 (18.9) |
| Bisphosphonate use (m) (%) ^c | 75 (39.3) | 65 (34.2) |
| Calcium use (m) (%) ^d | 106 (55.5) | 121 (63.7) |
| Vitamin D use (m) (%) ^e | 98 (51.3) | 109 (57.4) |
| Oral corticosteroid use (m) (%) ^f | 21 (11.0) | 18 (9.5) |
| Ethnicity (m) (%) | | |
| Caucasian | 178 (93.2) | 181 (95.3) |
| Hispanic | 8 (4.2) | 2 (1.1) |
| African American | 3 (1.6) | 4 (2.1) |
| Asian | 1 (0.5) | 2 (1.1) |
| Other | 1 (0.5) | 1 (0.5) |
| Smoking (m) (%) | | |
| Never | 92 (48.2) | 84 (44.2) |
| Former | 68 (35.6) | 84 (44.2) |
| Current | 31 (16.2) | 22 (11.6) |
| Index fracture location (m) (%) | n = 242 | n = 238 |
| Thoracic (T5–T9) | 56 (23.1) | 49 (20.6) |
| Thoracolumbar (T10–L2) | 143 (59.1) | 146 (61.3) |
| Lumbar (L3–L5) | 43 (17.8) | 43 (18.1) |
| Opioid use (m) (%) | n = 165 | n = 169 |
| | 122 (73.9) | 126 (74.6) |
| T-score (m) (%) | n = 165 | n = 160 |
| Normal (≥ -1) | 27 (16.4) | 27 (16.9) |
| Osteopenia (< -1 to ≥ -2.5) | 71 (43.0) | 71 (44.4) |
| Osteoporosis (< -2.5) | 67 (40.6) | 62 (38.8) |

Note:—(m) indicates numerator (No.) in category; IQR, interquartile range.

^a Groups were comparable at baseline for all variables.

^b Eight patients with kyphoplasty and 15 with vertebroplasty did not undergo surgery and are not included in the denominator.

^c For patients using bisphosphonates, at baseline, the median time of use was 24.0 months for each group.

^d For patients using calcium, at baseline, the median time of use was 42.0 and 48.0 months for each group, respectively.

^e For patients using vitamin D, at baseline, the median time of use was 36.0 months for each group.

^f For patients using oral corticosteroids, at baseline, the median time of use was 18.0 and 19.5 months for each group, respectively.